Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

239,507 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.
Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X. Wang H, et al. Among authors: zhang j, zhang z, zhang y. Cell. 2020 Aug 6;182(3):713-721.e9. doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6. Cell. 2020. PMID: 32778225 Free PMC article.
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
Xia S, Duan K, Zhang Y, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang Y, Zhang W, Yang Y, Chen W, Gao X, You W, Wang X, Wang Z, Shi Z, Wang Y, Yang X, Zhang L, Huang L, Wang Q, Lu J, Yang Y, Guo J, Zhou W, Wan X, Wu C, Wang W, Huang S, Du J, Meng Z, Pan A, Yuan Z, Shen S, Guo W, Yang X. Xia S, et al. Among authors: zhang l, zhang w, zhang h, zhang y. JAMA. 2020 Sep 8;324(10):951-960. doi: 10.1001/jama.2020.15543. JAMA. 2020. PMID: 32789505 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang H, Wang W, Zhang W, Li N, Xie Z, Ding L, You W, Zhao Y, Yang X, Liu Y, Wang Q, Huang L, Yang Y, Xu G, Luo B, Wang W, Liu P, Guo W, Yang X. Xia S, et al. Among authors: zhang w, zhang y. Lancet Infect Dis. 2021 Jan;21(1):39-51. doi: 10.1016/S1473-3099(20)30831-8. Epub 2020 Oct 15. Lancet Infect Dis. 2021. PMID: 33069281 Free PMC article. Clinical Trial.
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial.
Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani MM, Abdulrazzaq N, Al Nusair M, Hassany M, Jawad JS, Abdalla J, Hussein SE, Al Mazrouei SK, Al Karam M, Li X, Yang X, Wang W, Lai B, Chen W, Huang S, Wang Q, Yang T, Liu Y, Ma R, Hussain ZM, Khan T, Saifuddin Fasihuddin M, You W, Xie Z, Zhao Y, Jiang Z, Zhao G, Zhang Y, Mahmoud S, ElTantawy I, Xiao P, Koshy A, Zaher WA, Wang H, Duan K, Pan A, Yang X. Al Kaabi N, et al. Among authors: zhang y. JAMA. 2021 Jul 6;326(1):35-45. doi: 10.1001/jama.2021.8565. JAMA. 2021. PMID: 34037666 Free PMC article. Clinical Trial.
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial.
Guo W, Duan K, Zhang Y, Yuan Z, Zhang YB, Wang Z, Zhao D, Zhang H, Xie Z, Li X, Peng C, Zhang W, Yang Y, Chen W, Gao X, You W, Wang XW, Shi Z, Wang Y, Yang XQ, Zhang L, Huang L, Wang Q, Lu J, Yang YL, Guo J, Zhou W, Wan X, Wu C, Wang W, Du J, Nian X, Li XH, Huang S, Shen S, Xia S, Pan A, Yang X. Guo W, et al. Among authors: zhang l, zhang yb, zhang w, zhang h, zhang y. EClinicalMedicine. 2021 Aug;38:101010. doi: 10.1016/j.eclinm.2021.101010. Epub 2021 Jul 7. EClinicalMedicine. 2021. PMID: 34250456 Free PMC article.
Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial.
Xia S, Zhang Y, Wang Y, Wang H, Yang Y, Gao GF, Tan W, Wu G, Xu M, Lou Z, Huang W, Xu W, Huang B, Wang W, Zhang W, Li N, Xie Z, Zhu X, Ding L, You W, Zhao Y, Zhao J, Huang L, Shi X, Yang Y, Xu G, Wang W, Liu P, Ma M, Qiao Y, Zhao S, Chai J, Li Q, Fu H, Xu Y, Zheng X, Guo W, Yang X. Xia S, et al. Among authors: zhang w, zhang y. Lancet Infect Dis. 2022 Feb;22(2):196-208. doi: 10.1016/S1473-3099(21)00462-X. Epub 2021 Sep 15. Lancet Infect Dis. 2022. PMID: 34536349 Free PMC article. Clinical Trial.
Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.
Kaabi NA, Yang YK, Zhang J, Xu K, Liang Y, Kang Y, Su JG, Yang T, Hussein S, ElDein MS, Shao S, Yang SS, Lei W, Gao XJ, Jiang Z, Wang H, Li M, Mekki HM, Zaher W, Mahmoud S, Zhang X, Qu C, Liu DY, Zhang J, Yang M, Eltantawy I, Xiao P, Wang ZN, Yin JL, Mao XY, Zhang J, Liu N, Shen FJ, Qu L, Zhang YT, Yang XM, Wu G, Li QM. Kaabi NA, et al. Among authors: zhang yt, zhang j, zhang x. Signal Transduct Target Ther. 2022 Jun 6;7(1):172. doi: 10.1038/s41392-022-00984-2. Signal Transduct Target Ther. 2022. PMID: 35665745 Free PMC article. Clinical Trial.
Immunogenicity Evaluating of the Multivalent COVID-19 Inactivated Vaccine against the SARS-CoV-2 Variants.
Zhang Y, Tan W, Lou Z, Huang B, Zhou W, Zhao Y, Zhang J, Liang H, Li N, Zhu X, Ding L, Guo Y, He Z, He Y, Wang Z, Ma B, Ma M, Zhao S, Chang Z, Zhao X, Zheng X, Wu G, Wang H, Yang X. Zhang Y, et al. Among authors: zhang j. Vaccines (Basel). 2022 Jun 16;10(6):956. doi: 10.3390/vaccines10060956. Vaccines (Basel). 2022. PMID: 35746564 Free PMC article.
239,507 results
You have reached the last available page of results. Please see the User Guide for more information.